Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 94.60% | 8.72% | -38.17% | -10.04% | -49.10% |
| Gross Profit | -94.60% | -8.72% | 38.17% | 10.04% | 49.10% |
| SG&A Expenses | 0.56% | 5.58% | -37.28% | 12.70% | 3.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.15% | 7.40% | -37.76% | -0.13% | -24.37% |
| Operating Income | -34.15% | -7.40% | 37.76% | 0.13% | 24.37% |
| Income Before Tax | -36.89% | -5.82% | 30.39% | -10.90% | 30.70% |
| Income Tax Expenses | -86.11% | 4,893.64% | 11,666.67% | 405.03% | 3,380.69% |
| Earnings from Continuing Operations | -20.42% | -17.81% | 28.66% | -12.85% | 20.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.42% | -17.81% | 28.66% | -12.85% | 20.23% |
| EBIT | -34.15% | -7.40% | 37.76% | 0.13% | 24.37% |
| EBITDA | -34.06% | -7.39% | 37.80% | 0.16% | 24.38% |
| EPS Basic | 11.76% | 10.70% | 54.81% | 29.29% | 56.76% |
| Normalized Basic EPS | -0.27% | 19.73% | 55.89% | 30.53% | 62.45% |
| EPS Diluted | 11.76% | 10.70% | 54.81% | 29.29% | 56.76% |
| Normalized Diluted EPS | -0.27% | 19.73% | 55.89% | 30.53% | 62.45% |
| Average Basic Shares Outstanding | 36.50% | 31.91% | 57.90% | 59.55% | 84.46% |
| Average Diluted Shares Outstanding | 36.50% | 31.91% | 57.90% | 59.55% | 84.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |